Prominent publications by Anthony Edward Lang

KOL Index score: 19084

BACKGROUND: The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear.

OBJECTIVE: To compare initial treatment with pramipexole vs levodopa in early Parkinson disease, followed by levodopa supplementation, with respect to the development of dopaminergic motor complications, other adverse events, and functional and quality-of-life outcomes.

DESIGN: Multicenter, parallel-group, double-blind, randomized controlled trial.

SETTING: Academic movement disorders ...

Conhecido por Initial Treatment |  parkinson disease |  pramipexole levodopa |  dopaminergic therapy |  randomized controlled
KOL Index score: 18793

It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). The objective of this work was to investigate whether combined pre- and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT ...

Conhecido por Dopamine Transporter |  msa psp |  posterior putamen |  progressive tomography |  receptor spect
KOL Index score: 17367

BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study.

METHODS: ADAGIO was a placebo-controlled, double-blind, multicentre, delayed-start study, in which 1176 patients with untreated early Parkinson's disease were randomly assigned to receive ...

Conhecido por Adagio Study |  updrs scores |  36 weeks |  rasagiline placebo |  week difference
KOL Index score: 16813

BACKGROUND: A therapy that slows disease progression is the major unmet need in Parkinson's disease.

METHODS: In this double-blind trial, we examined the possibility that rasagiline has disease-modifying effects in Parkinson's disease. A total of 1176 subjects with untreated Parkinson's disease were randomly assigned to receive rasagiline (at a dose of either 1 mg or 2 mg per day) for 72 weeks (the early-start group) or placebo for 36 weeks followed by rasagiline (at a dose of either 1 ...

Conhecido por 1 Day |  updrs score |  week earlystart |  early treatment |  rasagiline parkinsons disease
KOL Index score: 15443

BACKGROUND: There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.

METHODS: In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2-receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive ...

Conhecido por Ropinirole Levodopa |  dyskinesia patients |  early parkinsons disease |  initial treatment |  aged parkinson
KOL Index score: 15239

BACKGROUND: Increased neuronal activity in the subthalamic nucleus and the pars interna of the globus pallidus is thought to account for motor dysfunction in patients with Parkinson's disease. Although creating lesions in these structures improves motor function in monkeys with induced parkinsonism and patients with Parkinson's disease, such lesions are associated with neurologic deficits, particularly when they are created bilaterally. Deep-brain stimulation simulates the effects of a ...

Conhecido por Globus Pallidus |  subthalamic nucleus |  pars interna |  patients parkinsons disease |  motor function
KOL Index score: 15029

Noninvasive brain stimulation studies have shown abnormal motor cortical plasticity in Parkinson's disease (PD). These studies used peripheral nerve stimulation paired with transcranial magnetic stimulation (TMS) to primary motor cortex (M1) at specific intervals to induce plasticity. Induction of cortical plasticity through stimulation of the basal ganglia (BG)-M1 connections has not been studied. In the present study, we used a novel technique of plasticity induction by repeated ...

Conhecido por Cortical Plasticity |  subthalamic nucleus |  transcranial magnetic |  dbs tms |  parkinsons disease
KOL Index score: 14777

This study examines the effect of apomorphine (APO), a nonselective D(1)- and D(2)-dopamine receptor agonist, on the firing activity of neurons in the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi) in patients with Parkinson's disease (PD). Single-unit microelectrode recordings were conducted in 13 patients undergoing implantation of deep brain stimulation electrodes in STN and 6 patients undergoing a pallidotomy. Doses of APO (2.5-8 mg) were sufficient to ...

Conhecido por Globus Pallidus |  subthalamic nucleus |  gpi stn |  neurons patients |  firing rate
KOL Index score: 14504

BACKGROUND: Mutations in LRRK2, the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?

METHODS: Researchers from 21 ...

Conhecido por Mutations Lrrk2 |  national institute |  genetic penetrance |  parkinson disease |  motor symptoms
KOL Index score: 14271

Parkinsonism, as a gradually progressive disorder, has a prodromal interval during which neurodegeneration has begun but cardinal manifestations have not fully developed. A systematic direct assessment of this interval has never been performed. Since patients with idiopathic REM sleep behaviour disorder are at very high risk of parkinsonism, they provide a unique opportunity to observe directly the development of parkinsonism. Patients with idiopathic REM sleep behaviour disorder in an ...

Conhecido por Behaviour Disorder |  rem sleep |  disease prodromal |  purdue pegboard |  patients parkinsonism
KOL Index score: 13752

The ability to dynamically use various aspects of cognition is essential to daily function, and reliant on dopaminergic transmission in cortico-striatal circuitry. Our aim was to investigate both striatal and cortical dopaminergic changes in patients with Parkinson's disease with mild cognitive impairment, who represent a vulnerable group for the development of dementia. We hypothesized severe striatal dopamine denervation in the associative (i.e. cognitive) region and cortical D2 ...

Conhecido por Mild Cognitive Impairment |  striatal dopamine |  parkinsons disease |  cortical thickness |  patients parkinson
KOL Index score: 13660

BACKGROUND: Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinson's disease.

METHODS: In this randomized, double-blind, placebo-controlled trial, we evaluated 361 patients with early Parkinson's disease who were assigned to receive carbidopa-levodopa at a daily dose of 37.5 and 150 mg, 75 and 300 mg, or ...

Conhecido por Levodopa Placebo |  progression parkinsons disease |  updrs baseline |  daily dose |  40 weeks
KOL Index score: 13609

This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve ...

Conhecido por Clinimetric Testing |  movement disorder society |  rating scale |  unified parkinson |  mdsupdrs updrs
KOL Index score: 13212

OBJECTIVE: The response of patients with dystonia to pallidal procedures is not well understood. In this study, we assessed the postoperative outcome of patients with primary and secondary dystonia undergoing pallidotomy or pallidal deep brain stimulation.

METHODS: Fifteen patients with dystonia had pallidal surgery (lesions or deep brain stimulation). These included nine patients with primary dystonia (generalized and cervical dystonias) and six with secondary dystonia (generalized, ...

Conhecido por Primary Dystonia |  pallidal deep |  brain stimulation |  pallidus humans |  6 months

Pessoas importantes para Parkinson Disease

Principais kols do mundo
Andrew **** ******
parkinsons disease progressive supranuclear motor fluctuations
Anthony ****** ****
parkinson disease movement disorders subthalamic nucleus
Werner * *****
parkinson disease multiple atrophy restless legs syndrome
Christopher * *****
parkinson disease movement disorders rating scales
Charles * ******
parkinson disease oxidative stress motor complications
Joseph * ********
movement disorders parkinson disease essential tremor

Anthony Edward Lang:Impacto especializado

Conceitos para os quaisAnthony Edward Langtem influência direta:Parkinson disease,  Parkinsons disease,  Movement disorders,  Subthalamic nucleus,  Deep brain stimulation,  Globus pallidus,  Progressive supranuclear,  Essential tremor.

Anthony Edward Lang:Kol Impact

Conceitos relacionados ao trabalho de outros autores para os quaisfor which Anthony Edward Lang tem influência:Parkinson disease,  Deep brain stimulation,  Subthalamic nucleus,  Movement disorders,  Basal ganglia,  Essential tremor,  Motor symptoms.



Este é o seu perfil? manage_accounts Reivindique seu perfil content_copy Copiar URL code Incorporar link para o seu perfil

Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital and Division of Neurology, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada | Department of Me